#ACC21 – RCT: Clopidogrel better than aspirin for chronic maintenance monotherapy after percutaneous coronary intervention.

Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial – The Lancet (free registration required)

Commentaries: Harmonizing Optimal Strategy for Treatment of coronary artery diseases-EXtended Antiplatelet Monotherapy – HOST-EXAM – American College of Cardiology AND Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM – TCTMD

Video: Dr. Hyo-Soo Kim and Dr. C. Michael Gibson Discuss: Aspirin Vs. Clopidogrel During Chronic Maintenance Monotherapy After Percutaneous Coronary Intervention: The Host Exam Randomized Controlled Trial

Commentary on Twitter

The sensational news of the day comes from South Korea. In a timely comparison of single antiplatelet monotherapies, clopidogrel beats aspirin during the chronic maintenance period after PCI, with curves diverging at 9 months. #ACC21https://t.co/Pp49LxcNWf pic.twitter.com/J9Un4QHzgL

— Davide Capodanno (@DFCapodanno) May 16, 2021